Mersana Therapeutics, Inc. Appoints John H. van Duzer, Ph.D., as Vice President of Manufacturing and Pharmaceutical Sciences

    CAMBRIDGE, Mass., Jan. 16 /CNW/ -- Mersana, a cancer therapeutics
company, announced today that John H. van Duzer, Ph.D. has joined the company
as Vice President of Manufacturing & Pharmaceutical Sciences.
    "John van Duzer adds a critical component to the Mersana management team
with his manufacturing and development experience," said Julie A. Olson,
Ph.D., President and CEO at Mersana. "As a clinical development-stage company,
manufacturing plays a key role in the advancement of our products and John's
contributions will impact our entire pipeline. We are also fortunate that
John's early experience in research enables the seamless transition of
candidates from research into development."
    Dr. van Duzer has over eighteen years of experience in pharmaceutical
R&D. As a Vice President of Manufacturing at ActivBiotics, he led efforts for
the development of a liquid dosage form of a rifamycin, an oral antibacterial
agent. Prior to joining ActivBiotics, Dr. van Duzer served as the Director of
Chemistry at Inotek Corporation, a clinical-stage, drug development company.
Prior to joining Inotek, Dr. van Duzer worked as a medicinal chemist in the
research group of Ciba-Geigy and subsequently Novartis for twelve years. Most
notable is his invention of lumiracoxib, a COX-2 inhibitor currently sold in a
number of countries. He is a co-author of over a dozen scientific publications
and is an inventor on numerous US and international patents. He received his
BA in Chemistry from the University of Pennsylvania and his Ph.D. in Organic
Chemistry from Yale University.
    About Mersana Therapeutics, Inc.
    Mersana, a privately held, venture backed company, utilizes its
proprietary nanotechnology platform to transform existing and experimental
anti-cancer agents into new, patentable drugs with superior pharmaceutical
properties. The key component of Mersana's platform is Fleximer(R), a novel,
biodegradable and bio-inert polymer hat can be chemically linked to small
molecules and biologics. Mersana's pipeline includes XMT-1001, a Fleximer-
camptothecin conjugate which is currently in Phase 1 clinical trials, and
several preclinical oncology compounds. Mersana's investors include Fidelity
Biosciences, ProQuest Investments, Rho Ventures, Harris & Harris Group and
PureTech Ventures.
    Fleximer(R) is a trademark of Mersana Therapeutics, Inc.

For further information:

For further information: Pete Leone, Chief Operating Officer of Mersana 
Therapeutics, Inc., +1-617-498-0020; or Media, Kathryn Morris of KMorrisPR for
 Mersana Therapeutics, Inc., +1-845-635-9828,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890